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Abstract
Background: While there are a variety of identifiable causes of constipation, even idiopathic constipation has different
possible mechanisms. Sennosides, the main laxative constituents of Daio, an ancient Kampo medicine, are prodrugs that are
converted to an active principle, rheinanthrone, by intestinal microbiota. In this study, we aimed to determine the sennoside
hydrolysis ability of lactic acid bacterial strains and bifidobacteria in the intestine and to investigate their effect on intestinal
peristalsis in mice.
Methodology/Principal Findings: A total of 88 lactic acid bacterial strains and 47 bifidobacterial strains were evaluated for
their ability to hydrolyze sennosides. Our results revealed that 4 strains, all belonging to the genus Bifidobacterium, had
strong sennoside hydrolysis ability, exhibiting a decrease of .70% of sennoside content. By thin-layer chromatography
analysis, rheinanthrone was detected in the medium cultured with B. pseudocatenulatum LKM10070 and B. animalis subsp.
lactis LKM512. The fecal sennoside contents significantly (P,0.001) decreased upon oral administration of these strains as
compared with the control. Intestinal peristalsis activity was measured by the moved distance of the charcoal powder
administered orally. The distance travelled by the charcoal powder in LKM512-treated mice was significantly longer than
that of control (P,0.05). Intestinal microbiota were analysed by real-time PCR and terminal-restriction fragment length
polymorphism. The diversity of the intestinal microbiota was reduced by kanamycin treatment and the diversity was not
recovered by LKM512 treatment.
Conclusion/Significance: We demonstrated that intestinal peristalsis was promoted by rheinanthrone produced by
hydrolysis of sennoside by strain LKM512 and LKM10070.
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Introduction
Constipation is a common clinical problem that can be
difficult to manage. It has a variety of identifiable causes, but
even idiopathic constipation has different possible mechanisms.
Chronic idiopathic constipation (CIC) is a common condition,
with a prevalence of 4% to 20% in cross-sectional community-
based surveys in developed countries [1–5]. Constipation is
both a symptom and, when chronic, a multisymptom disorder,
and it can overlap with other gastrointestinal tract disorders
such as dyspepsia and gastro-esophageal reflux disease.
Furthermore, one should keep in mind the possibility of cancer
and be alert for its warning signs [6]. Therefore, in the last 10
years, novel drug therapies have been developed for constipa-
tion, particularly for CIC [7]. Since ancient times, Kampo
medicine daio (Rhei rhizoma or Sennae folium) has been employed
as a purgative crude drug because of its purgative properties.
Sennoside A and B, the main laxative constituent of daio,a r e
prodrugs that are converted to an active principle, rheinan-
throne, by intestinal microbiota [8–11]. Therefore, there is a
considerable difference in the efficacy of this drug among
individuals. Further, if the patient’s intestinal microbiota cannot
hydrolyse sennoside A and/or B to rheinanthrone, this
treatment would be ineffective. In contrast, certain patients
experience diarrhoea as a side effect of daio medicine. Since
1970, several studies have been performed to investigate the
relationship between sennosides and intestinal microbiota and
the metabolism of sennosides [8,12,13]. The bacterial strains
that can hydrolyse sennosides were isolated from intestines [14–
16], and these microbiota have been found to employ several
pathways to metabolize sennosides [13]. However, to the best of
our knowledge, no study has been conducted with regard to the
effect of daio/sennosides in combination with intestinal micro-
biota on intestinal peristalsis.
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31700Figure 1. Time schedule of animal assay. These tests were performed individually (one mouse/cage). (A) Sennoside-hydrolysing test by
Bifidobacterium spp. Feces were collected every 2 hours. (B) Intestinal peristalsis promotion test by LKM512. This test was performed using a pair of
mice: 1 LKM512-administered mouse and 1 control mouse.
doi:10.1371/journal.pone.0031700.g001
Figure 2. Ability of lactic acid bacterial strains and bifidobacterial strains to hydrolyse Sennoside A and B. Sennoside-hydrolysing
values were expressed as the ratio of sennoside content in the medium without bacterial strain to that in the medium with bacterial strain.
doi:10.1371/journal.pone.0031700.g002
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PLoS ONE | www.plosone.org 2 February 2012 | Volume 7 | Issue 2 | e31700In this study, we used lactic acid bacteria and Bifidobacterium spp.
isolated from fermented milk and human feces, screened them for
their ability for sennoside hydrolysis and investigated their effect in
combination with the strains on intestinal peristalsis in mice.
Materials and Methods
Bacterial strains
A total of 88 lactic acid bacterial strains belonging to the genera
Lactobacillus, Leuconostoc, Lactococcus, Enterococcus, and Streptococcus
were used in this study. Of these, 82 strains were isolated from
several fermented milk samples from all parts of the world, 3 were
industrial starter cultures used for the manufacture of fermented
milk, and 3 were obtained from the Japan Collection of
Microorganisms (JCM; RIKEN, Saitama, Japan). A total of 47
bifidobacterial strains belonged to the species Bifidobacterium
adolescentis, B. longum, B. breve, B. bifidum, B. catenulatum, B.
pseudocatenulatum, and B. animalis subsp. lactis, including strains
isolated from the feces of healthy adults [17]; 1 was a probiotic
strain with many health-promoting effects; and 4 were obtained
from the JCM. These bacterial strains were isolated in another
study performed in 2,000, more than 10 years ago [17]. We
obtained permission to stock and use isolated strains in the future
from volunteers enrolled to the old study in 2,000.
Strains of lactic acid bacteria were pre-incubated aerobically at
37uC for 48 hours in Lactobacilli MRS broth (Becton Dickinson)
or GYP agar [18]. Bifidobacterium strains were pre-incubated on
blood-liver (BL) agar (Nissui Pharmaceutical, Tokyo, Japan) at
37uC for 72 hours under anaerobic conditions with the aid of an
AnaeroPack Anaero system (Mitsubishi Gas Chemical, Tokyo,
Japan).
Assay of sennosides hydrolysis by bacterial strains
Sennoside A or B (Wako) was added to MRS or GYP liquid
medium (final concentration: 50 mg/ml) and sterilized by filtration.
The medium was added into the wells of a 24-well plate (Nunc),
and one bacterial colony on the pre-cultured plate was inoculated
in the wells and cultured at 37uC for 48 hours under anaerobic
conditions using the AnaeroPack Anaero system. After cultivation,
the culture medium was centrifuged at 12,0006g for 10 minutes,
and the supernatant was stored at 280uC until use. Areas of
Sennoside A and B in the supernatant of the media before and
after cultivation were quantified by high-performance liquid
chromatography (HPLC), and the sennoside hydrolysis rates were
determined from the results.
HPLC conditions
HPLC separation was conducted on a Waters Alliance 2696
system (Waters, MA, USA) equipped with an autosampler, a
temperature-controlledcolumn, and Waters2487 Dual Absorbance
Detector working at 340 nm. Sennosides were separated on a
Inertsil ODS-3 column (3 mm I.D. 6250 mm, particle size 4 mm,
GL Science, CA, USA). The mobile phase consisted of acetonitrile/
phosphoric acid. The gradient profiles were as follows: 0 min 14:86,
10 min 14:86, 28 min 35:65, 29 min 80:20, 34 min 80:20. The
flow-rate was 0.8 ml/min. The column temperature was 50uC.
Thin-layer chromatography analysis for rheinanthrone in
culture medium
The bacterial strains were added to sennoside-containing
culture broth and cultured at 37uC for 35 hours. At the end of
the incubation period, the growth was arrested by adding 1% p-
nitroso-N,N9-dimethylaniline. After being maintained at room
temperature for 10 min, the mixture was centrifuged at 16,000 g
for 5 min. Chloroform (1 ml) was then added to the supernatant
(2 ml), the mixture was vigorously shaken, and centrifuged again
at 300 g for 10 min. The chloroform layer was removed and
filtered [15]. Aliquots (5 ml) were loaded onto silica gel 60 (Merck),
which was developed using n-propanol:ethyl acetate:water
(40:40:30) as the solvent [19]. After drying for 30 min,
rheinanthrone was visualised by spraying with ammonia solution.
The rheinanthrone spot on the silica gel was visualised as a yellow-
coloured spot, and its Rf value was measured.
Mice
Male and female 12- to 15-week-old Crj:CD-1 (ICR) mice bred
from same parents (first delivery: 15 weeks, second delivery: 25
weeks) obtained from Japan SLC Inc. (Hamamatsu, Japan) were
used. Plastic cages containing hardwood bedding were used
(22563386140 mm
3; Clea Japan, Inc. Tokyo, Japan); 5 mice
were housed per cage. The mice were kept on a 12-hour light/
dark cycle at 2561uC in conventional conditions. They were
provided with a standard pellet chow diet (CRF-1, Oriental Yeast
Co. Ltd., Tokyo, Japan) ad libitum. All animal experiments were
approved by the Kyodo Milk Animal Use Committee (Permit
Number: 2008-03) and were in accordance with the Guide for the
Care and Use of Laboratory Animals, published by the National
Academies Press.
Sennoside hydrolysis assay in mouse intestine by
Bifidobacterium strains
The timeline of the assay is presented in Figure 1A. Kanamycin
was orally administered to the mice 2 times for 2 days in order to
damage their normal intestinal bacteria (75 mg/d per mouse;
Wako, Tokyo, Japan), because the normal intestinal microbiota of
Figure 3. Detection of rheinanthrone in sennoside-containing
medium cultivated by bifidobacterial strain LKM10070 or
LKM512 by thin-layer chromatography (TLC). Spots of rheinan-
throne were coloured yellow, and the Rf value was 0.68.
doi:10.1371/journal.pone.0031700.g003
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antibioticchosen because it is not absorbed from the intestine by the
body [20]. B. pseudocatenulatum LKM10070 (initially designated as
strainM8duringthescreening)and B.animalissubsp.lactisLKM512
solutions were harvested from BL agar containing the cell cultures
by swabbing and suspending the swabbed culture in phosphate-
buffered saline (PBS). Ninety minutes after the last administration of
kanamycin, the mice were orally administered these solutions
(0.4 ml/mouse; 5610
8–1610
9 cfu/mouse). To avoid any genetic
variations, 8 males and 9 females born from the same parents were
administered B. pseudocatenulatum LKM10070 and B. animalis subsp.
lactis LKM512, respectively. Ninety minutes after administration,
the mice were orally administered sennoside A dissolved in sodium
hydrogen carbonate (0.75 mg/mouse). Thereafter, feces discharged
werecollected every 2 hoursfor upto8 hours and storedat 220uC.
Control mice were administered PBS without bacterial cells. The
blank test was performed without kanamycin administration. Briefly
themiceweretreated with PBSnotcontainingbacterialcellsbutdid
not receive kanamycin.
From the feces, sennoside A was extracted by shaking the
obtained feces sample in 5 ml methanol (70%) for 30 min. After
extraction, the supernatant was obtained by centrifugation at
1,500 g for 10 min, and the precipitate was extracted again using
the same method. The supernatants were mixed, filtered
(0.45 mm), and stored at 220uC until sennoside mesurement.
Animal assay of intestinal peristalsis
The timeline of the assay is presented in Figure 1B. This assay
was performed using 10 male mice and B. animalis subsp. lactis
LKM512. The mice were orally administered kanamycin,
LKM512 or PBS (control), and sennoside A in order to assay
sennoside hydrolysis in the intestine by Bifidobacterium strains.
After 4 hours, the mice were orally administered 0.4 ml of 5%
charcoal powder suspended in 10% gum arabic solution. After
100 minutes, the mice were sacrificed using diethyl ether, and
the gastrointestinal tracts were obtained. Intestinal peristalsis
activity was expressed as the distance of the charcoal powder
from the end of the ileum (i.e. the base of the caecum or start of
the colon) to the start of the charcoal powder measured using a
ruler. Each pair of mice, of which one was administered
LKM512 and the other was used as the control, was assayed
simultaneously, and each pair was assayed one after the other
because of the exact time line required to be followed during the
assay.
Real-time PCR for quantitative determination of bacterial
cell numbers
Fecal specimens were collected from the mice before the
treatment, after kanamycin administration (1.5 hours after the last
dose of kanamycin), and 3 and 6 hours after LKM512
administration. Bacterial DNA was isolated from 20 mg feces
using the methods described by Matsuki et al. [21]. For obtaining
the total bacterial count and B. animalis subsp. lactis count, real-
time PCR was performed using the StepOne real-time PCR
system (Applied Biosystems, CA, USA) as described in our
previous report [22], with minor modification. Briefly, SYBRH
Premix Ex Taq
TM II was used instead of SYBRH Premix Ex Taq. The
primer sets used are shown in Supplementary Table S1.
Figure 4. Sennoside hydrolysis in the intestine by bifidobacterial strain LKM10070 (A) and LKM512 (B) administered orally after
kanamycin treatment. Feces were collected every 2 hours up to 8 hours. The total sennoside contents in feces discharged up to 8 hours after
administration of sennoside were significantly higher in kanamycin-treated mice than in the blank (no kanamycin) (p,0.001). These tests for the
blank group were performed before kanamycin treatment. The amount of sennoside collected from the feces of mice administered LKM10070 (n=8)
or LKM512 (n=9) was significantly lower than that collected from the feces of control mice (p,0.001, Mann-Whitney U test). Bars indicate the average
value. The times of dosages are shown in Materials and Methods section and in Figure 1.
doi:10.1371/journal.pone.0031700.g004
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fragment length polymorphism (T-RFLP)
T-RFLP analysis using 529F primer labelled at the 59-end with
6-carboxyfluorescein was performed as described in our previous
report [22] with some modifications. Briefly, 50 ng of the purified
PCR products was digested with 0.25 units of HaeIII (Takara) at
37uC for 3 hours. The PCR products and the restriction digest
products were purified by GenElute PCR Clean-Up Kit (Sigma).
The terminal-restriction fragment (T-RF) length was determined
using a 1200LIZ standard size marker (Applied Biosystems) in a
3130 Genetic Analyzer (Applied Biosystems) and with the aid of
Gene Mapper software v4.0 (Applied Biosystems).
Statistical analysis
The fecal sennoside contents were compared using Mann-
Whitney U tests. The distance travelled by the charcoal powder
measured in the intestinal peristalsis assay was compared using a
modified Wilcoxon signed-rank test. StatMate IV (ATMS Co.
Ltd., Tokyo, Japan) was used to conduct all the statistical analyses.
Results
Screening of sennoside-hydrolysing bacterial strains
Thequantityof sennoside Aand B inthe medium aftercultivation
was expressed as area ratio (culture with bacterium/culture without
bacterium). In 5 of the 88 lactic acid bacterial strains (Figure 2A) and
21 of the 47 bifidobacterial strains (Figure 2B), the sennoside content
of the medium had decreased over 20%, suggesting that these strains
have the ability to hydrolyse sennosides. Specifically, Bifidobacterium
strains 33, 38, 42, and M8 had strong sennoside hydrolysis ability; in
thesestrains,adecreaseof.70%ofsennosidecontentwasobserved.
After screening these 4 strains, we selected B. pseudocatenulatum M8
(hereafter referred to as LKM10070; the 16S rRNA sequence of this
strain was read and renamed for the stock) because it had the
strongest acid tolerance among all the 4 strains (data not shown). We
also selected B. animalis subsp. lactis LKM512 due to its moderate
ability of sennoside hydrolysis. While LKM10070 hydrolyses
sennoside rapidly, LKM512 hydrolyses it at a slow rate. LKM512
exhibits potent acid tolerance [23] and the ability to adhere to
human intestinal mucin [24], and it alters the intestinal microbial
populations [25]. The bacterial counts of both LKM10070 and
LKM512 in the liquid medium after cultivation were 10
9 cfu/ml.
By thin-layer chromatography (TLC), rheinanthrone was
detected as yellow spots with Rf values of 0.68 in the medium
cultured with LKM10070 or LKM512; this value was almost the
same as the reference value 0.64 (Figure 3) [19].
Sennosides hydrolysis in the intestine by Bifidobacterium
strains
The total sennoside contents in feces discharged up to 8 hours
after sennoside administration were 2.261.1, 117.5628.7, and
56.3628.2 mg in the blank, control, and LKM10070 group,
respectively. Levels in the LKM10070 group were significantly
decreased as compared with the blank (p,0.001) and the control
(p,0.001) groups (Figure 4A). The total sennoside contents in feces
discharged up to 8 hours after sennoside administration in the
blank, control, and LKM512 group were 6.664.1, 68.4622.1,
and 4.461.3 mg, respectively. Levels in the LKM512 group were
significantly decreased as compared with the blank (p,0.001) and
the control (p,0.001) groups (Figure 4B). These results indicate
that bifidobacterial strains hydrolyzed sennoside in the intestine
(Figure 4). Mice in which the fecal sennoside content decreased
discharged loose feces; further, almost all the mice (7 out of 8 mice)
treated with LKM10070 had diarrhea.
Promotion of intestinal peristalsis by LKM512
This study was performed using LKM512, because the laxative
ability of LKM10070 was too strong in the sennoside hydrolysis
test. An example of this test is shown in Figure 5. In almost all
pairs, the distance travelled by the charcoal powder was greater in
LKM512-treated mice than in the controls (n=5), similar to that
shown in Figure 5A. The distance travelled by the charcoal
powder from the end of the ileum in LKM512-treated mice was
significantly longer than that of control (p,0.05) (Figure 5B).
Effect of LKM512 on intestinal microbiota after
kanamycin treatment
The intestinal bacterial count is shown in Figure 6A. The total
bacterial count before the test and after kanamycin administration
was 3.461.0610
11 cells/g of feces and 1.660.6610
11 cells/gof feces,
respectively, showing a slight decrease in the intestinal microbial
count upon kanamycin treatment. Furthermore, the total bacterial
count did not recover until 6 hours after LKM512 administration.
The number of B. animalis subsp. lactis (LKM512) before treatment
was below the detection limit (10
3 cells/g of feces). At 3 and 6 hours
after LKM512 administration, these values were 6.861.8610
9 cells/
gf e c e s ,a n d1 . 8 61.3610
9 cells/g of feces, respectively.
Figure 6B shows the typical T-RFLP profiles prior to the
treatment, after kanamycin treatment, and at 6 hours after
Figure 5. Effects of B. animalis subsp. lactis LKM512 on intestinal
peristalsis of mice administered sennoside after kanamycin
treatment. (A) Picture of the intestinal tract. The activity of intestinal
peristalsis was expressed as the distance travelled by the charcoal
powder from the end of the ileum (i.e. the base of the caecum or start
of the colon) to the top of the charcoal powder, measured using a ruler.
(B) Comparison of the length of charcoal powder from the end of the
ileum. This value was significantly longer in LKM512-adminstered mice
(n=5) than in the control (n=5) (p,0.05), modified Wilcoxon signed-
rank test). Error bars show the standard error of the mean.
doi:10.1371/journal.pone.0031700.g005
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ments (T-RFs) were obtained from the feces before the treatment,
only 7 T-RFs were detected from the feces after kanamycin
treatment, indicating that the diversity of the intestinal microbiota
was reduced by kanamycin treatment. Although 230 bp T-RF,
which was predicted to bederived fromLKM512,was detectedafter
LKM512 supplementation, the pattern of the other T-RFs detected
was the same as that obtained in the T-RFLP after kanamycin
treatment. Although there are individual differences in the T-RFLP
profile of feces before treatment, the diversity of the intestinal
microbiota was reduced by kanamycin treatment and the 230-bp T-
RF was commonly detected after LKM512 supplementation.
Discussion
Postoperative hospitalized patients or elderly individuals
experience flaccid constipation, which is characterized by weak
muscular activity (i.e. intestinal peristalsis) in the colon. Therefore,
promotion of intestinal peristalsis using the sennoside-containing
Kampo medicine Daio is an effective treatment. However, majority
of such at-risk individuals frequently take antibiotics to prevent
bacterial infection, consequently damaging the intestinal microbi-
ota. [26] This explains why daio does not effectively treat
constipation in many patients. Therefore, since our study involved
experiments using mice treated with kanamycin, this study is very
clinically relevant.
Two known pathways exist for sennoside metabolism by
intestinal microbiota [14,15,27]. In the first pathway, sennosides
A and B are first hydrolysed to sennidin A and sennidin B via
sennidin A monoglucoside and sennidin B monoglucoside,
respectively, by b-D-glucosidase; this is followed by reduction to
produce rheinanthrone, a genuine purgative component. In the
second pathway, sennosides are first reduced to 8-glucosyl-
rheinanthrone and then hydrolysed by b-D-glucosidase(s) to
produce rheinanthrone [14,15,27]. Intestinal bacterial species
and strains which hydrolyse sennoside to sennidin, such as
Figure 6. Effects of kanamycin and LKM512 administration after kanamycin treatment on intestinal microbiota. (A) Change in the
number of total bacteria and B. animalis subsp. lactis LKM512 in feces. Since the detection limit of the standard curve is 10
3 cells, bacterial counts
below this limit were assigned a value of 10
3 cells/g of feces. (B) Change in the T-RFLP profile after kanamycin treatment (middle) and LKM512
administration after kanamycin treatment (lower) on digestion with HaeIII. Arrow indicates T-RF predicted to be derived from LKM512.
doi:10.1371/journal.pone.0031700.g006
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Bifidobacterium adolescentis [14], and which hydrolysed sennidin to
rheinanthrone, such as C. sphenoides, Clostridium perfringens, B.
adolescentis, Eubacterium limosum, Streptococcus intermedius (=Peptostrep-
tococcus intermedius), and Lactococcus lactis subsp. lactis (=Lactobacillus
xylosus), were found [15]. From these reports, although sennoside
appears to be hydrolysed to rheinanthrone in a stepwise manner
by sennoside-hydrolysing bacteria and sennidin-reducing bacteria,
C. sphenoides and B. adolescentis seem to have the ability to hydrolyse
sennoside to rheinanthrone independently. B. pseudocatenulatum
(LKM10070) and B. animalis subsp. lactis (LKM512) also are
capable of hydrolysing sennoside to rheinanthrone.
No other study has tested bacterial strains involved in sennoside
metabolism in vivo. These bacteria have to tolerate gastric juices
and reach the lower intestinal tract after being ingested in order to
be able to hydrolyse sennoside. LKM10070 and LKM512 have
sufficient acid tolerance; in particular, we demonstrated that
LKM512 exhibits potent acid tolerance [23] and the ability to
adhere to intestinal mucin [24] and alter the human intestinal
microbial populations [25]. In this study, B. animalis subsp. lactis
(LKM512) was detected in the order of 10
10 cells/g of feces,
indicating that this strain was likely able to hydrolyze sennoside in
the intestine of mice.
Oral administration of kanamycin resulted in a decrease in
sennoside-hydrolysing bacteria already present in the intestine,
since kanamycin results in a decrease in the intestinal microbial
population and the disappearance of their diversity (Figure 6).
However, because more than 10
11 cells/g feces had survived after
kanamycin treatment, the disappearance of the intestinal micro-
biota diversity probably contributes to the decrease in sennoside
hydrolysis to a greater extent than does reduction of the intestinal
bacterial population. The disappearance of diversity of intestinal
microbiota implies downregulation of rheinanthrone production
by the bacterial consortium that may contain sennoside-hydrolys-
ing bacteria and sennidin-reducing bacteria. Facultative anaerobic
bacteria, e.g., Lactobacillus or Enterobacteriaceae, which are among
the commensal bacteria in the intestine of young mice, are the
organisms that might have had an influence on sennoside
hydrolysis since kanamycin does not have much effect on obligate
anaerobic bacteria.
After oral administration of LKM512, we detected the T-RF
which was predicted to be derived from this strain; however, the
T-RF pattern was almost the same as that obtained after
kanamycin treatment, indicating that the increased hydrolysis of
kanamycin is most likely a direct result of the action of LKM512;
however, there remains the possibility that administration of the
strain has an indirect effect of causing alterations in the
subdominant microbiota, which are undetectable by T-RF
analysis. To the best of our knowledge, this is the first report
demonstrating that orally administered bacterial strains promote
intestinal peristalsis by producing rheinanthrone from sennoside in
the intestine. B. animalis subsp. lactis LKM512 should be used in
future clinical trials to treat constipation in postoperative
hospitalized patients and elderly individuals.
Although positive effects were obtained by following the time
schedule (Figure 1B), intestinal peristalsis were not promoted when
LKM512 and sennoside were administered orally at the same time
(data not shown). This indicates that sennoside passed through and
was discharged from the colon without being hydrolysed before
LKM512 could be activated in the intestine. For stable effects,
further studies are required to determine an appropriate time of
administration.
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